2.Anti-CD36 Mediated Platelet Transfusion Refractoriness and Related Cases After Stem Cell Transplantation.
Yan ZHOU ; Li-Lan LI ; Zhou-Lin ZHONG ; Xue-Jun LIU ; Jin-Lian LIU ; Wei-Dong SHEN ; Guo-Guang WU
Journal of Experimental Hematology 2018;26(2):541-546
OBJECTIVETo analyse the cases of platelet transfusion refractoriness after received HLA-matched unrelated donor hematopoietic stem cell transplantation, to analyze and identify the phenotype and genotype of CD36 in both the patient and stem cell donor, as well as the characteristic of antibody induced platelet transfusion refractoriness, and to analyse the efficacy of matched CD36-deficiency platelets transfusions.
METHODSThe CD36 expression on platelet and monocyte was analyzed by flow cytometry (FCM) in both patient and donor. Polymerase chain reaction sequence-based typing (PCR-SBT) was used to analyze the exons sequence of CD36 and HPA. Fast monoclonal antibody-specific immobilization of platelet antigen (F-MAIPA) and FCM were used to identify platelet antibodies in the patient. Short tandem repeat polymerase chain reaction (STR-PCR) was applied to monitor engraftment evidence. The platelet level was monitored. CD36- deficiency donor's platelets were selected from CD36- deficiency donor blood bank.
RESULTSThe donor was CD36 positive and the patient was typed I CD36 deficiency. The anti-CD36 antibody was identified in patient's serum (after transplantation), while the HLA and HPA-related antibodies were excluded. Sequence analysis of CD36 exon in the patient showed Exon 6 -1G>C(Change in splicing site) homozygote, which was a novel CD36 mutation. STR, HPA and CD36 of the patient (complete chimerism) were conversed to that of donor gene types on day 18 after allo-HSCT. The positive CD36 expression on platelet and monocyte in the patient was observed on day 96 after allo-HSCT. The patient showed the platelet transfusion refractoriness which was significantly improved after platelets transfusions from CD36 deficiency donors.
CONCLUSIONStem cell transplants resulted in anti-CD36 and caused platelet transfusion refractoriness, that was first reported in China. To ensure the efficacy of platelet transfusion, the CD36-deficiency patient should receive CD36 deficiency platelets for transfusion.
Antigens, Human Platelet ; Blood Platelet Disorders ; Blood Platelets ; CD36 Antigens ; China ; Humans ; Platelet Transfusion ; Thrombocytopenia
3.A Case of Gray Platelet Syndrome.
Sun Min LEE ; Joon Seong PARK ; Young Ae LIM ; Sung Ran CHO
The Korean Journal of Laboratory Medicine 2005;25(5):290-293
Gray platelet syndrome (GPS) is one of primary hemostatic disorders with characteristics of moderate bleeding tendency, thrombocytopenia, gray platelet on Wright-Giemsa stained smear and absence of platelet -granule. It is known to be mostly inherited by autosomal dominance but not all. We report a case of gray platelet syndrome diagnosed in a woman with bleeding tendency such as easy bruise and evaluate clinical usefulness of mean platelet component (MPC), mean platelet volume (MPV) and platelet component distribution width (PCDW) using ADVIA 120 (Bayer Diagnostics, NY, USA).
Blood Platelets
;
Contusions
;
Female
;
Gray Platelet Syndrome*
;
Hemorrhage
;
Hemostatic Disorders
;
Humans
;
Mean Platelet Volume
;
Thrombocytopenia
4.CD36 Antigen Deficiency and Platelet Transfusion.
Hai-Yan LI ; Yan ZHOU ; Wei-Dong SHEN
Journal of Experimental Hematology 2016;24(3):934-938
CD36 is a transmembrane glycoprotein, a multi-ligand receptor, possesses various biological functions. CD36 deficiency may stimulate the body to produce anti-CD36 alloimmune antibodies through the several pathways, such as blood transfusion, pregnancy or organ transplantation and so on, leading to the refractoriness of immune platelet transfusion and other diseases. The recent research advances of CD36 deficiency and its molecular biological basis, platelet transfusion and CD36 antibody detection are summarized briefey in this review.
Autoantibodies
;
blood
;
Blood Platelet Disorders
;
Blood Platelets
;
Blood Transfusion
;
CD36 Antigens
;
deficiency
;
Female
;
Genetic Diseases, Inborn
;
Histocompatibility
;
Humans
;
Platelet Transfusion
;
Pregnancy
5.Molecular polymorphism Analysis on CD36 Deficiency among Platelet Blood Donors in Shenzhen.
Yun-Ping XU ; Ze-Tao SUN ; Long PENG ; Shuang LIANG ; Fan WU ; Zhen LI ; Da-Cheng LI
Journal of Experimental Hematology 2022;30(3):884-889
OBJECTIVE:
To analyze the molecular polymorphisms of CD36 among 58 blood donors with CD36 deficiency and compare with CD36 positive controls.
METHODS:
A total of 58 donors with CD36 deficiency during a screening conducted in the laboratory from September 2019 to December 2020 were enrolled as the test group, including 39 males and 19 females, while 120 platelet donors with CD36 positive were randomly selected as the controls, including 76 males and 44 females. All of the subjects were Han nationality. The PCR-SBT method was used to detect coding region of CD36 gene, and molecular mutations were compared with those CD36 positive controls.
RESULTS:
Among the 58 donors with CD36 deficiency, mutations appears in 32 individuals. The detection rate for type I was 71.43% (5/7), and type II was 51.92% (27/52), while among the 120 controls, mutations appears in 12 donors (10%). In the CD36 antigen-deficient donors, 16 variations were found, in which 329-330 del AC with the highest frequency accounted for 20.69%, followed by 1228-1239 del ATTGTGCCTATT(15.52%) and 1156 C>T(10.34%). Two variations, 198-205 del GATCTTTG and 220 C>T, led to premature termination of translation; four mutations, 329-330 del AC, 560 ins T, 1011-1049 39bp dupl and 1343-1344 ins TCTT, caused translation frame shift; 1228-1239 del ATTGTGCCTATT led to deletion of four amino acids (Ile-Val-Pro-Ile) at sites 410-413 of the peptide chain. The 1140 T>A and 1275 G>A were synonymous mutations, and the other 7 mutations resulted in the substitution of single nucleotide. The platelet expression in the donors of CD36 positive with 329-330 del AC or 1228-1239 del ATTGTGCCTATT mutation (heterozygote) was lower than those CD36 positive individuals without mutations (homozygote).
CONCLUSION
Multiple gene mutations in the CD36 coding region may cause CD36 deficiency, and the heterozygous individuals with mutations may lead to CD36 antigen reduction or deletion. Mutation is not detected in 44.83% of CD36 deficient individuals, there may be some other reasons for the CD36 antigen deficiency.
Blood Donors
;
Blood Platelet Disorders/metabolism*
;
Blood Platelets/metabolism*
;
CD36 Antigens/metabolism*
;
Female
;
Genetic Diseases, Inborn
;
Humans
;
Male
6.In-stent thrombosis in a patient with left main stem stenosis and platelet disorder.
Yi-tong MA ; Ding HUANG ; Yi-ning YANG
Chinese Journal of Cardiology 2010;38(5):466-467
Aged
;
Blood Platelet Disorders
;
complications
;
therapy
;
Coronary Artery Disease
;
complications
;
therapy
;
Humans
;
Male
;
Stents
;
Thrombosis
;
etiology
7.Two Novel Mutations at the CD36 Gene Splicing Sites and Their Molecular Basis for the CD36 Deficiency.
Li-Lan LI ; Jie-Run CHEN ; Li-Hong JIANG ; Zhou-Lin ZHONG ; Hai-Yan LI ; Yan ZHOU ; Fang LU ; Guo-Guang WU
Journal of Experimental Hematology 2020;28(6):2056-2065
OBJECTIVE:
To study two novel CD36 gene mutations at the CD36 splicing sites found in Guangxi population, as well as the molecular basis and population incidence of them.
METHODS:
DNA sequencing and cDNA clonal sequencing were used to detect CD36 exon sequence and the protein coding region sequence of CD36 mRNA for 2 CD36 deficient individuals (HHC and WGM) found in Guangxi population. Eukaryotic expression cell lines were established for the discovery of CD36 mRNA abnormal transcripts and Western blot assay was used to verify the effect of abnormal CD36 mRNA transcripts on CD36 expression. A DNA PCR-SSP genotyping method was established for the two CD36 novel mutations, and the population distribution was investigated among 110 CD36 deficient individuals in Guangxi region and 296 random individuals in Guangxi population.
RESULTS:
Novel mutation of c.430 -1G>C was found at the CD36 splicing site in HHC and WGM individuals, and novel mutation of c.1006 +2T>G at the CD36 splicing site was also found in the WGM individual. CD36 cDNA clonal sequencing showed that CD36 c.430 -1G>C could lead to the production of the two CD36 mRNA transcript variants: c.429_430ins[430-17_430-2;C](p.Ala144fsTer1) and c.430_609del(p.Ala144_Pro203del)(GenBank:HM 217023.1); and CD36 c.1006 +2T>G could lead to the production of CD36 mRNA transcript variant of c.819_1006 del (p.Ser274GlufsTer16) (GenBank: HM217025.1). It was verified that all the three transcript variants could lead to CD36 deficiency by establishment of eukaryotic expression cell lines and Western blot assay. A study of the population incidence of two novel CD36 splicing site mutations found showed that in 110 CD36 deficient individuals and in 296 random individuals in Guangxi region, the mutation rate of CD36 c.430 -1G>C was 10.91% (12/110) and 1.35% (4/296), respectively, while CD36 c.1006 +2T>G was 2.73% (3/110) and 0 (0/296), respectively.
CONCLUSION
This study identifies two novel CD36 mutations at CD36 splicing site, and preliminary clarified their molecular basis for the CD36 deficiency and the distribution characteristics in Guangxi population as well. It provides an experimental and theoretical basis for studying the molecular mechanism and characteristics of CD36 deficiency in Chinese population.
Blood Platelet Disorders
;
China
;
Genetic Diseases, Inborn
;
Humans
;
Mutation
;
RNA Splicing
8.Establishment of method detecting CD36 expression on human platelet and its application.
Ying LIU ; Xian-Guo XU ; Xiao-Fei LAN ; Kai-Rong MA ; Shu CHEN ; Xiao-Zhen HONG ; Ji HE ; Fa-Ming ZHU ; Hang-Jun LYU
Journal of Experimental Hematology 2013;21(4):1042-1045
The individual with the deficiency of CD36 antigen on platelet displayed the risk of anti-CD36 immune reaction induced by transfusion, which is one of the reasons for platelet transfusion refractoriness (PTR). This study was purposed to detect the expression level of CD36 antigen on platelet by flow cytometry among apheresis platelet donors of Hangzhou area, and the frequency of CD36 deficiency was analyzed. Platelet-rich plasma (PRP) was separated from fresh anticoagulant whole blood by centrifugation, then the platelets were washed and adjusted to 1×10(6). The platelets were incubated with FITC-labeled CD36 and PE-labeled CD41 monoclonal antibodies, then the expression level of CD36 was detected by flow cytometry. The CD36 expression on monocytes for the samples of CD36-deficiency on the platelets was further analyzed. The results showed that 7 samples with CD36 antigen deficiency were found in 192 apheresis platelet donors. The frequency of CD36 deficiency was 3.6% and all of them were typeII deficiency. The significant difference of CD36 antigen expression was observed in the platelet donors of Hangzhou population, among them 59 individuals with low expressed CD36 antigen and 126 individuals with highly expressed CD36 antigen were found according to the geometric mean fluorescence intensity. It is concluded that the CD36 antigen deficient phenotype existed in the population, these data will provide the information for research of the CD36 antigen distribution and help to solve the platelet transfusion refractoriness.
Blood Platelet Disorders
;
diagnosis
;
Blood Platelets
;
metabolism
;
CD36 Antigens
;
metabolism
;
Flow Cytometry
;
methods
;
Genetic Diseases, Inborn
;
diagnosis
;
Humans
9.Orthostatic Intolerance and Coagulation Abnormalities: An Update.
Wei QUAN ; Yuchen WANG ; Selena CHEN ; Junbao DU
Neuroscience Bulletin 2019;35(1):171-177
10.Report of a patient with spontaneous aggregation of his giant and morphologically abnormal platelets.
Zhaoyue WANG ; Jumei SHI ; Yue HAN ; Yingchun WANG ; Xia BAI ; Dingwei LU ; Changgeng RUAN
Chinese Journal of Hematology 2002;23(3):121-125
OBJECTIVETo study the pathological and clinical characteristics of a patient with spontaneous platelet aggregation of his giant and morphologically abnormal platelets.
METHODSPlatelet size and structure were observed under light microscope and electron microscope. Platelet aggregation was measured turbidometrically. Platelet glycoproteins (GP) were analyzed using flow cytometry. PCR and DNA sequencing were performed to identify the gene abnormality.
RESULTSThe patient had spontaneous platelet aggregation of giant platelets with thickened plasma membrane and increased number of granules in various shapes. Aspirin and ticlopidine did not affect the spontaneous aggregation. The expression of GP I b, GP II b, GP III a and P-selectin in the platelet membrane were in normal range. Results of gene analyses for GP I balpha, GP I bbeta and GPIX were also normal.
CONCLUSIONBoth morphological and functional abnormalities of the platelets from the patient were clearly distinguishable from that of other hereditary giant platelet disorders. It would probably represent a novel platelet disorder which had not been reported to date.
Aspirin ; pharmacology ; Bernard-Soulier Syndrome ; metabolism ; pathology ; Blood Platelet Disorders ; metabolism ; pathology ; Cell Size ; physiology ; Child ; Cytoplasmic Granules ; pathology ; ultrastructure ; Female ; Humans ; Platelet Aggregation ; drug effects ; physiology ; Platelet Aggregation Inhibitors ; pharmacology ; Platelet Membrane Glycoproteins ; genetics ; metabolism ; Ticlopidine ; pharmacology